Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

June 15, 2026 15:00 ET | Source: Confo Therapeutics

Confo Therapeutics Announces Encouraging Preclinical Data for Post-bariatric Hypoglycemia Candidate CFTX-2034 at ENDO 2026

Confo Therapeutics shared promising preclinical data for CFTX-2034, a potential first-in-class treatment for post-bariatric hypoglycemia, at ENDO 2026.
December 18, 2025 05:00 ET | Source: Confo Therapeutics

Confo Therapeutics Nominates SSTR5 Agonist Antibody CFTX-2034 as Development Candidate for Post-Bariatric Hypoglycemia

Confo Therapeutics nominates SSTR5 agonist antibody CFTX-2034 as its development candidate for post-bariatric hypoglycemia (PBH).